Hutchmed’s divestiture; Xgene reports Phase 2b win for non-opioid pain drug

Plus, news about Hookipa and Capricor Therapeutics:

Hutchmed divests 45% stake in Chinese company: Hutchmed will get about $608 million in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

AbbVie and Umoja to develop new CAR-T therapies for cancer

Share this article Under the initial deal, AbbVie will obtain a sole licensing option for CD19-directed in-situ generated CAR-T cell therapy candidates of Umoja. Credit:

January 5, 2024

Revolutionary blood test monitors gene expression dynamics in the brain

The brain is the most protected organ in the body, sheathed in a complex and nearly impenetrable barrier of specialized blood vessels.

January 11, 2024

Loss of abdominal fat may be key to reversing prediabetes

Prediabetes is a condition that precedes type 2 diabetes and increases the risk of heart attack, kidney and eye disease, and several types of cancer.

September 28, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.